Isabella Manni

Isabella Manni

Auto-generated profile, based on publicly available information

Isabella Manni

UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2001 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GDGabriella D'Orazi
Gabriella D'Orazi
BCBarbara Cecchinelli
Barbara Cecchinelli
TBTiziana Bruno
Tiziana Bruno
IMIsabella Manni
Isabella Manni
YHYuichiro Higashimoto
Yuichiro Higashimoto
SSSilvia Soddu
Silvia Soddu

1 July 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KJKarsten Jürchott
Karsten Jürchott
SBStephan Bergmann
Stephan Bergmann
Ulrike SteinUlrike Stein
Ulrike Stein
WWWolfgang Walther
Wolfgang Walther
MJMartin Janz
Martin Janz
HRHans-Dieter Royer
Hans-Dieter Royer
Expression of the Y-box protein YB-1 is increased in proliferating normal and cancer cells, but its role in cell proliferation and cell cycle progression is unclear. We have identified a cell cycle-dependent relocalization of YB-1 from the cytoplasm to the nucleus at the G1/S phase transition and demonstrate that both the charged zipper and the cold shock domain are involved in regulating this process. Using cell lines that constitutively overexpress YB-1, we show that nuclear accumulation of YB-1 is associated with increased cyclin A and cyclin B1 mRNA and protein expression. We provide evidence that deregulated YB-1 expression is linked to adhesion-independent cell proliferation through the induction of cyclin A. Thus, we have identified YB-1 as a cell cycle stage-specific transcription factor important for cell proliferation.

1 February 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
IMIsabella Manni
Isabella Manni
GMGiuseppina Mazzaro
Giuseppina Mazzaro
Aymone GurtnerAymone Gurtner
Aymone Gurtner
RMRoberto Mantovani
Roberto Mantovani
UHUlrike Haugwitz
Ulrike Haugwitz
GPGiulia Piaggio
Giulia Piaggio
During normal cell cycles, the function of mitotic cyclin-cdk1 complexes, as well as of cdc25C phosphatase, is required for G2 phase progression. Accordingly, the G2 arrest induced by DNA damage is associated with a down-regulation of mitotic cyclins, cdk1, and cdc25C phosphatase expression. We found that the promoter activity of these genes is repressed in the G2 arrest induced by DNA damage. We asked whether the CCAAT-binding NF-Y modulates mitoticcyclins, cdk1, and cdc25C gene transcription during this type of G2 arrest. In our experimental conditions, the integrity of the CCAAT boxes ofcyclin B1, cyclin B2, and cdc25Cpromoters, as well as the presence of a functional NF-Y complex, is strictly required for the transcriptional inhibition of these promoters. Furthermore, a dominant-negative p53 protein, impairing doxorubicin-induced G2 arrest, prevents transcriptional down-regulation of the mitotic cyclins, cdk1, and cdc25C genes. We conclude that, as already demonstrated for cdk1, NF-Y mediates the transcriptional inhibition of the mitotic cyclins and the cdc25C genes during p53-dependent G2 arrest induced by DNA damage. These data suggest a transcriptional regulatory role of NF-Y in the G2 checkpoint after DNA damage.

11 March 1999 in Oncogene
Verified
Journal Article
Closed access
FBFabrizio Bolognese
Fabrizio Bolognese
MWMark Wasner
Mark Wasner
CDChristine Lange-Zu Dohna
Christine Lange-Zu Dohna
Aymone GurtnerAymone Gurtner
Aymone Gurtner
ARAntonella Ronchi
Antonella Ronchi
KEKurt Engeland
Kurt Engeland

1 May 2017 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
Aymone GurtnerAymone Gurtner
Aymone Gurtner
IMIsabella Manni
Isabella Manni
GPGiulia Piaggio
Giulia Piaggio

25 March 2016 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LMLaura Mercurio
Laura Mercurio
MCMaria Antonietta Ajmone Cat
Maria Antonietta Ajmone Cat
SCSerena Cecchetti
Serena Cecchetti
ARAlessandro Ricci
Alessandro Ricci
GBGiuseppina Bozzuto
Giuseppina Bozzuto
LMLuisa Minghetti
Luisa Minghetti
The CXCL12/CXCR4 pathway regulates tumor cell proliferation, metastasis, angiogenesis and the tumor-microenvironment cross-talk in several solid tumors, including glioblastoma (GBM), the most common and fatal brain cancer. In the present study, we evaluated the effects of peptide R, a new specific CXCR4 antagonist that we recently developed by a ligand-based approach, in an in vitro and in vivo model of GBM. The well-characterized CXCR4 antagonist Plerixafor was also included in the study. The effects of peptide R on CXCR4 expression, cell survival and migration were assessed on the human glioblastoma cell line U87MG exposed to CXCL12, by immunofluorescence and western blotting, MTT assay, flow cytometry and transwell chamber migration assay. Peptide R was then tested in vivo, by using U87MG intracranial xenografts in CD1 nude mice. Peptide R was administered for 23 days since cell implantation and tumor volume was assessed by magnetic resonance imaging (MRI) at 4.7 T. Glioma associated microglia/macrophage (GAMs) polarization (anti-tumor M1 versus pro-tumor M2 phenotypes) and expressions of vascular endothelial growth factor (VEGF) and CD31 were assessed by immunohistochemistry and immunofluorescence. We found that peptide R impairs the metabolic activity and cell proliferation of human U87MG cells and stably reduces CXCR4 expression and cell migration in response to CXCL12 in vitro. In the orthotopic U87MG model, peptide R reduced tumor cellularity, promoted M1 features of GAMs and astrogliosis, and hindered intra-tumor vasculature. Our findings suggest that targeting CXCR4 by peptide R might represent a novel therapeutic approach against GBM, and contribute to the rationale to further explore in more complex pre-clinical settings the therapeutic potential of peptide R, alone or in combination with standard therapies of GBM.